ARS PHARMACEUTICALS
ALK and ARS Pharma Partner to Co-Promote Neffy, First Needle-Free Epinephrine Nasal Spray for Anaphylaxis
ALK and ARS Pharmaceuticals have entered a four-year co-promotion agreement for Neffy, the only FDA-approved needle-free epinephrine nasal spray for treating anaphylaxis, targeting 9,000 US pediatricians.
FDA Sets PDUFA Date for Lower-Dose Neffy Nasal Spray in Young Pediatric Patients with Anaphylaxis
The FDA has set a PDUFA target action date of March 6, 2025, for ARS Pharmaceuticals' sNDA for a 1 mg dose of Neffy (epinephrine nasal spray).
FDA Approves Novel Therapies for Pediatric Conditions: Eosinophilic Esophagitis, Anaphylaxis, and Atopic Dermatitis
Dupilumab (Dupixent) gains FDA approval as the first treatment specifically for children aged 1-11 with eosinophilic esophagitis, addressing a critical unmet need for this age group.
ARS Pharmaceuticals' Neffy® Filed for Approval in China, Japan, and Australia
ARS Pharmaceuticals' licensing partners have filed for approval of Neffy® (epinephrine nasal spray) in China, Japan, and Australia.
ARS Pharmaceuticals продвигает Neffy для лечения анафилаксии и расширяет глобальное партнерство
ARS Pharmaceuticals активно продвигает Neffy (назальный спрей эпинефрина) в США в качестве первого и единственного безъигольного лечения анафилаксии.
FDA Approves Neffy, Needle-Free Epinephrine Nasal Spray Developed by ARS Pharmaceuticals
ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, has received FDA approval, offering a needle-free alternative to EpiPens for allergic reactions.
Neffy Pre-Orders Launch, Trofinetide Data Highlighted, and Screen Time Impact on Sleep Assessed
Pre-ordering has commenced for Neffy, an epinephrine nasal spray, offering a needle-free option for treating anaphylaxis in adults and children.
ARS Pharma's Neffy Aims to Expand Pediatric Access for Type 1 Allergic Reactions
ARS Pharmaceuticals seeks FDA approval for Neffy 1 mg to treat type 1 allergic reactions, including anaphylaxis, in children weighing 33-66 lbs..